Phan Jack, Hickey Miriam A, Zhang Peixiang, Chesselet Marie-Francoise, Reue Karen
Department of Human Genetics, David Geffen School of Medicine at UCLA, University of California, Los Angeles, CA 90095, USA.
Hum Mol Genet. 2009 Mar 15;18(6):1006-16. doi: 10.1093/hmg/ddn428. Epub 2009 Jan 5.
In addition to the hallmark neurological manifestations of Huntington's disease (HD), weight loss with metabolic dysfunction is often observed in the later stages of disease progression and is associated with poor prognosis. The mechanism for weight loss in HD is unknown. Using two mouse models of HD, the R6/2 transgenic and CAG140 knock-in mouse strains, we demonstrate that adipose tissue dysfunction is detectable at early ages and becomes more pronounced as the disease progresses. Adipocytes acquire a 'de-differentiated' phenotype characterized by impaired expression of fat storage genes. In addition, HD mice exhibit reduced levels of leptin and adiponectin, adipose tissue-derived hormones that regulate food intake and glucose metabolism. Importantly, some of these changes occur prior to weight loss and development of some of the characteristic neurological symptoms. We demonstrate that impaired gene expression and lipid accumulation in adipocytes can be recapitulated by expression of an inducible mutant huntingtin transgene in an adipocyte cell line and that mutant huntingtin inhibits transcriptional activity of the PGC-1alpha co-activator in adipocytes, which may contribute to aberrant gene expression. Thus, our findings indicate that mutant huntingtin has direct detrimental effects in cell types other than neurons. The results also indicate that circulating adipose-tissue-derived hormones may be accessible markers for HD prognosis and progression and suggest that adipose tissue may be a useful therapeutic target to improve standard of life for HD patients.
除了亨廷顿舞蹈症(HD)典型的神经学表现外,在疾病进展后期常观察到体重减轻及代谢功能障碍,且这与预后不良相关。HD患者体重减轻的机制尚不清楚。我们使用两种HD小鼠模型,即R6/2转基因小鼠和CAG140基因敲入小鼠品系,证明脂肪组织功能障碍在早期即可检测到,并随着疾病进展而愈发明显。脂肪细胞呈现出一种“去分化”表型,其特征为脂肪储存基因的表达受损。此外,HD小鼠体内瘦素和脂联素水平降低,这两种脂肪组织衍生的激素可调节食物摄入和葡萄糖代谢。重要的是,其中一些变化发生在体重减轻和一些典型神经症状出现之前。我们证明,在脂肪细胞系中表达可诱导的突变型亨廷顿蛋白转基因可重现脂肪细胞中基因表达受损和脂质积累的现象,且突变型亨廷顿蛋白会抑制脂肪细胞中PGC-1α共激活因子的转录活性,这可能导致异常基因表达。因此,我们的研究结果表明,突变型亨廷顿蛋白对神经元以外的细胞类型具有直接有害作用。研究结果还表明,循环中的脂肪组织衍生激素可能是HD预后和疾病进展的可检测标志物,并提示脂肪组织可能是改善HD患者生活质量的一个有用治疗靶点。